Drug Profile
SPN 802
Alternative Names: SPN802Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Supernus Pharmaceuticals
- Class Antiepileptic drugs
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bipolar disorders; Epilepsy
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Bipolar-disorders in USA
- 16 Jul 2016 No recent reports of development identified for phase-I development in Epilepsy in USA
- 25 Feb 2009 Phase-I clinical trials in Bipolar disorders in USA (unspecified route)